ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis
Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment– TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnologycompany focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy totreat a range of solid tumors, today announced … Continued
ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and IntermediateRisk Prostate Cancer at AUA 2025
Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in … Continued
ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP
Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC Additional podium presentation to provide updates from long-term evaluation of Padelipor n VTP in intermediate-risk prostate cancer TEL AVIV, Israel, April 11, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) … Continued
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2024
Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin n VTP in Low Grade UTUC at EMUC 2024
Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) — ImPact … Continued